
HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
Loading news...

HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Fourth Quarter and Full Year 2025 Results.

The collaboration will combine HeartBeam's patented ECG platform with Mount Sinai's artificial intelligence and clinical expertise to develop and validate advanced AI-ECG algorithms.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home.

SANTA CLARA--(BUSINESS WIRE)--HeartBeam to Attend Investor and Industry Conferences in March.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference.

HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.

HeartBeam, Inc.'s (NASDAQ: BEAT) stock is trading higher on Monday, with a session volume of 193.38 million compared to the average volume of 2.191 million as per data from Benzinga Pro.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment.

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application.

HeartBeam, Inc. ( BEAT ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Robert Eno - CEO, Chief Business Officer & Director Timothy Cruickshank - Chief Financial Officer Conference Call Participants Kyle Bauser - ROTH Capital Partners, LLC, Research Division William Sutherland - The Benchmark Company, LLC, Research Division Presentation Operator Greetings, and welcome to the HeartBeam Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2025 Results.

DENVER , Nov. 3, 2025 /PRNewswire/ -- SM Energy Company (the "Company") (NYSE: SM) today reported financial and operating results for the third quarter 2025 and provided certain full year and fourth quarter 2025 guidance. Highlights include: Strong Production Performance Continues: Production totaled 19.7 MMBoe, or 213.8 MBoe/d, including 113.9 MBbls/d of oil driven by consistent strong performance across all assets.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere.